WT1 and acute myeloid leukemia: reported that high WT1 expression after 1st induction chemotherapy would be associated with poor outcomes in pediatric AML patients, (5-year OS for WT1+ve was 54.5% vs 79.4% for WT1-ve patients, p=0.036), but multivariate analyses did not confirm it as an independent poor prognostic factor on the outcome of AML patients (OS, p=0.87 and EFS, p=0.92) (21).